Penumbra Inc PEN
We take great care to ensure that the data presented and summarized in this overview for Penumbra Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PEN
View all-
Black Rock Inc. New York, NY4.26MShares$1.19 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$1.07 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.79MShares$500 Million0.05% of portfolio
-
State Street Corp Boston, MA1.16MShares$324 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il971KShares$270 Million0.04% of portfolio
-
Baillie Gifford & CO909KShares$253 Million0.18% of portfolio
-
Rtw Investments, LP New York, NY866KShares$241 Million2.93% of portfolio
-
Jpmorgan Chase & CO New York, NY844KShares$235 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY758KShares$211 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA748KShares$208 Million0.01% of portfolio
Latest Institutional Activity in PEN
Top Purchases
Top Sells
About PEN
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Insider Transactions at PEN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2025
|
Harpreet Grewal Director |
SELL
Open market or private sale
|
Direct |
100
-1.17%
|
$29,200
$292.98 P/Share
|
|
Dec 01
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.13%
|
$177,000
$295.29 P/Share
|
|
Nov 26
2025
|
Arani Bose Director |
SELL
Bona fide gift
|
Indirect |
1,799
-0.65%
|
-
|
|
Nov 25
2025
|
Arani Bose Director |
SELL
Open market or private sale
|
Indirect |
7,500
-2.65%
|
$2,250,000
$300.19 P/Share
|
|
Nov 25
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
1,800
-2.71%
|
$540,000
$300.06 P/Share
|
|
Nov 21
2025
|
Arani Bose Director |
SELL
Open market or private sale
|
Indirect |
7,500
-1.29%
|
$2,175,000
$290.82 P/Share
|
|
Nov 17
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
3,580
+5.11%
|
-
|
|
Nov 17
2025
|
Lambert Shiu Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,580
+9.15%
|
-
|
|
Nov 17
2025
|
Maggie Yuen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,580
+17.78%
|
-
|
|
Nov 15
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
701
-0.55%
|
$196,280
$280.07 P/Share
|
|
Nov 15
2025
|
Lambert Shiu Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
852
-1.31%
|
$238,560
$280.07 P/Share
|
|
Nov 15
2025
|
Shruthi Narayan President |
SELL
Payment of exercise price or tax liability
|
Direct |
358
-1.33%
|
$100,240
$280.07 P/Share
|
|
Nov 15
2025
|
Maggie Yuen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
691
-2.56%
|
$193,480
$280.07 P/Share
|
|
Nov 10
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.13%
|
$159,600
$266.75 P/Share
|
|
Nov 04
2025
|
Harpreet Grewal Director |
SELL
Open market or private sale
|
Direct |
186
-2.14%
|
$42,222
$227.58 P/Share
|
|
Oct 15
2025
|
Shruthi Narayan President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,294
-4.58%
|
$326,088
$252.61 P/Share
|
|
Oct 02
2025
|
Harpreet Grewal Director |
SELL
Open market or private sale
|
Direct |
186
-2.09%
|
$46,128
$248.61 P/Share
|
|
Oct 01
2025
|
Thomas Wilder Director |
SELL
Open market or private sale
|
Direct |
186
-50.0%
|
$47,058
$253.93 P/Share
|
|
Oct 01
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.07%
|
$149,400
$249.84 P/Share
|
|
Sep 15
2025
|
Shruthi Narayan President |
BUY
Grant, award, or other acquisition
|
Direct |
9,170
+24.5%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 32.5K shares |
|---|---|
| Exercise of conversion of derivative security | 471K shares |
| Open market or private sale | 376K shares |
|---|---|
| Payment of exercise price or tax liability | 6.63K shares |
| Bona fide gift | 262K shares |